분자유전학실험실 (단국대학교 분자생물학과)

 이성욱 ( 2014-10-14 12:44:25 , Hit : 1925
 Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval


The first complete treatment for hepatitis C that requires taking only a once-a-day pill won approval Friday from the Food and Drug Administration.

The drug, called Harvoni from Gilead Sciences, could shorten the duration of treatment and provide the first all-oral regimen for many patients.

The new drug also appears to be a bit less expensive for some patients than Gilead’s existing blockbuster hepatitis C drug, Sovaldi, which has become the poster child for those complaining that the cost of medicines is out of control.

Sovaldi costs $1,000 a pill, or $84,000 for a typical 12-week course of treatment, but it must be used with other drugs. Harvoni is even more expensive at $1,125 a pill, or $94,500 for a 12-week course of treatment. But that is roughly in line with the total cost for Sovaldi and the drugs used with it. Many patients will be able to take Harvoni for only eight weeks, at a cost of about $63,000.

This will probably not mollify insurance companies and Medicaid programs, many of which are restricting the use of Sovaldi to the most seriously ill patients.


Harvoni may shorten  treatment for hepatitis C. Credit Gilead Sciences  

“They are not prepared to cover the cost even at $63,000,” said Dr. Steven Miller, the chief medical officer of Express Scripts, which manages pharmacy benefits for employers and insurance companies. “Their budgets just are not going to be able to tolerate it.”

He said the patients eligible for the shorter regimen are also the ones least in need of treatment.

But some patient advocates hope the pricing will persuade payers to relax their restrictions.

“We’re talking about a much lower cost to Medicaid for a substantial number of people, and to me that’s a game changer,” said Ryan Clary, executive director of the National Viral Hepatitis Roundtable, a coalition of organizations that receives some funding from drug companies.

Gilead defended the price. “We believe the price of Harvoni reflects the value of the medicine,” it said in a statement. “Unlike long-term or indefinite treatments for other chronic diseases, Harvoni offers a cure at a price that will significantly reduce hepatitis C treatment costs now and deliver significant health care savings to the health care system over the long term.”

Harvoni is a combination of sofosbuvir, the ingredient in Sovaldi, and a new medicine from Gilead called ledipasvir, which is not available as a stand-alone product. The two drugs attack the virus in different ways.

By combining drugs into a single pill, Gilead is repeating the strategy it used to become the leading supplier of drugs for H.I.V. Its drug Atripla, which combines three medicines, was the first once-a-day complete treatment for that disease.

Gilead estimates that over the long run as many as half of the patients might be able to receive only eight weeks of treatment.

Three million to four million Americans are infected with hepatitis C, which can gradually damage the liver. Harvoni’s approval is only for the main subtype of hepatitis, called genotype 1, which accounts for about 70 percent of the cases in the United States.

Continue reading the main story Continue reading the main story

Continue reading the main story

In clinical trials, more than 90 percent of the patients treated with Harvoni had no detectable virus in their blood 12 weeks after treatment ended. Doctors say that is considered an effective cure.

Sovaldi, which was approved in December, has already made a huge difference for patients, reducing the duration of treatment to 12 weeks from 24 or 48 weeks, increasing the cure rate and reducing side effects.

But Sovaldi is not supposed to be used by itself. Patients with genotype 1 are supposed to also take the older hepatitis C drugs, alpha interferon and ribavirin. Interferon in particular, which is given as a weekly injection, can have debilitating side effects such as flulike symptoms and depression.

In practice, many doctors this year have been avoiding the use of interferon by prescribing Sovaldi with another new pill, Johnson & Johnson’s Olysio. That combination has not been approved by the F.D.A. and costs about $150,000.

Compared with that off-label combination, Harvoni is far less expensive, which could mean lower sales for Johnson & Johnson’s drug.

It is not so much the price per patient of Sovaldi but the total cost that has insurers and Medicaid programs worried. Sales of Sovaldi in the first half of the year were nearly $6 billion, almost all of it in the United States, shattering the record for first-year sales of any drug.

“Ironically, if this drug were not a breakthrough drug, people would not object to it because so many people would not be standing in line,” said Ed Schoonveld, a principal at ZS Associates, a consultant to drug companies.

Caught off guard by the surge in demand, many insurers and state Medicaid programs have started to restrict the use of Sovaldi to patients who have more advanced liver disease. Some are requiring patients to demonstrate they have not abused alcohol or illicit drugs in a number of months.

Some advocacy groups, led by the National Viral Hepatitis Roundtable, sent a letter last month to Sylvia Mathews Burwell, the secretary of health and human services, saying that such restrictions were “discriminatory and violate the spirit and the intent of the Affordable Care Act.”

It can take 20 years or more for hepatitis C to cause noticeable cirrhosis or liver cancer. Many people infected with the virus never suffer noticeable liver damage.

That is why in many cases it can be acceptable for patients without advanced liver damage to delay treatment. Many patients, on advice from their doctors, have been delaying treatment until Harvoni became available.

Gilead and some doctors make the case that even if liver damage is not serious, people with a chronic virus infection can have various other health problems, including an increased risk of heart attack. Treating the disease early is better, they argue, because it avoids liver damage to begin with.

“The sooner you cure them, the more likely you are to have better long-term outcomes for these patients,” John F. Milligan, president and chief operating officer of Gilead, said at the Morgan Stanley health care conference last month.

Gilead recently agreed to allow several generic drug manufacturers in India to make and sell much less expensive copies of Sovaldi in about 90 poorer countries. That agreement also applies to Harvoni.

Analysts think the introduction of Harvoni will keep Gilead in the lead in the market for hepatitis C treatments. Just this week, Bristol-Myers Squibb said it would essentially give up for now on fielding its own combination treatment, a tacit acknowledgment that its regimen would not be competitive.

The competition for Gilead is expected from AbbVie, which could receive F.D.A. approval for its combination regimen by the end of this year. Insurers hope to play Gilead and AbbVie against each other to obtain lower prices, but it is not clear that will work.

967   피부암 외에도 다른 위험성이 있는 햇빛  이성욱 2014/10/24 1563
966   Novartis Extends Deal to Use SomaLogic Proteomics Technology  이성욱 2014/10/23 1367
965   여성은 남성보다 현명한 의사결정자일까?  이성욱 2014/10/23 1530
964   스위칭 오프할 수 있는 리보자임(ribozyme)의 개발과 유전자치료 (우리실험실 결과소개)  이성욱 2014/10/17 2407
963   간에 암 전이가 어떻게 발생하는가  이성욱 2014/10/17 1774
962   CAR T 세포를 이용한 효과적인 항암 치료법  이성욱 2014/10/15 2139
  Harvoni, a Hepatitis C Drug From Gilead, Wins F.D.A. Approval  이성욱 2014/10/14 1925
960   20년간 숨어 있던 폐암의 비밀  이성욱 2014/10/14 1553
959   특정 염색체 구조가 중요 유전자 조절  이성욱 2014/10/14 1947
958   초파리로 인체 대장암의 특징을 보여준다  이성욱 2014/10/12 1733
957   2014년 노벨 화학상: 세포의 내부생활을 드러낸 혁신적 현미경  이성욱 2014/10/12 2142
956   2014년 노벨 생리의학상 수상자  이성욱 2014/10/12 1536
955   CRISPR/Cas9 Can Now Edit RNA, Not Just DNA  이성욱 2014/10/07 1483
954   대장암 종양 성장과 밀접한 마이크로 알앤에이  이성욱 2014/10/06 1631
953   신약 개발을 위한 Cas9 동물 모델의 개발  이성욱 2014/10/02 1611
952   암확산을 중단시키는 박테리아 소통시스템  이성욱 2014/09/29 1361
951   단일 돌연변이가 망막 종양으로 이어지는 이유  이성욱 2014/09/29 1383
950   베를린 환자가 HIV 감염에서 완치된 이유  이성욱 2014/09/29 1518
949   유전자요법을 이용한 신경근육접합부 결함 치료  이성욱 2014/09/24 1727
948   전령 RNA에서의 슈도유리딜화  이성욱 2014/09/19 1785

[이전 10개] [1]..[11][12][13][14][15] 16 [17][18][19][20]..[64] [다음 10개]

Copyright 1999-2024 Zeroboard / skin by ROBIN